CoChat

Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost‐effectiveness analysis

Open access
Klebanoff, Matthew J., Corey, Kathleen E., Chhatwal, Jagpreet, Kaplan, Lee M., Chung, Raymond T., Hur, Chin · 2017 · Hepatology
Cited by 91

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Nonalcoholic steatohepatitis (NASH) affects 2%‐3% of the US population and is expected to become the leading indication for liver transplantation in the next decade. Bariatric surgery may be an effective but expensive treatment for NASH. Using a state‐transition model, our analysis assessed the effectiveness and cost‐effectiveness of surgery to manage NASH. We simulated the benefits and harms of laparoscopic Roux‐en‐Y gastric bypass surgery in patients defined by weight class (overweight, mild obesity, moderate obesity, and severe obesity) and fibrosis stage (F0‐F3). Comparators included intensive lifestyle intervention (ILI) and no treatment. Quality‐adjusted life years (QALYs), costs, and incremental cost‐effectiveness ratios were calculated. Our results showed that surgery and ILI in obese patients (with F0‐F3) increased QALYs by 0.678‐2.152 and 0.452‐0.618, respectively, compared with no treatment. Incremental cost‐effectiveness ratios for surgery in all F0‐F3 patients with mild, moderate, or severe obesity were $48,836/QALY, $24,949/QALY, and $19,222/QALY, respectively. In overweight patients (with F0‐F3), surgery increased QALYs by 0.050‐0.824 and ILI increased QALYs by 0.031‐0.164. In overweight patients, it was cost‐effective to reserve treatment only for F3 patients; the incremental cost‐effectiveness ratios for providing surgery or ILI only to F3 patients were $30,484/QALY and $25,367/QALY, respectively. Conclusions: Surgery was both effective and cost‐effective for obese patients with NASH, regardless of fibrosis stage; in overweight patients, surgery increased QALYs for all patients regardless of fibrosis stage, but was cost‐effective only for patients with F3 fibrosis; our results highlight the promise of bariatric surgery for treating NASH and underscore the need for clinical trials in this area. (H epatology 2017;65:1156‐1164).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.28958

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

Metadata

Authors
Klebanoff, M. J., Corey, K. E., Chhatwal, J., Kaplan, L. M., Chung, R. T., & Hur, C.
Venue
Hepatology
Published
2017-02-21
Volume
65
Issue
4
Pages
1156-1164
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W2556792033
Cited by
91
References
17
FWCI
11.95
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.